Sales of Losec fell by 3% in the first quarter of the year, the company has announced. The patent for the drug ends this year.
However, within the gastrointestinal market, this was offset by other factors, including trade stocking of Nexium ahead of its launch in the USA.
Total gastrointestinal sales increased by 2%. In other areas sales increased by 15% in the USA and 7% in Europe.
|Sales of Losec have fallen by 3%.
The company's pre-tax profits increased to 1.09 billion US dollars from 934 million dollars a year earlier - a 17% increase.
The company is predicting a decline in its sales and earnings growth in the current quarter because of costs of research and development and launching new products.
Report Copyright: Englemed Health News at http://www.internationalmedicalnews.com